| Gaucher Disease, Type 1
Zavesca vs Cerezyme
Side-by-side clinical, coverage, and cost comparison for gaucher disease, type 1.Deep comparison between: Zavesca vs Cerezyme with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCerezyme has a higher rate of injection site reactions vs Zavesca based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cerezyme but not Zavesca, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zavesca
Cerezyme
At A Glance
Oral
Three times daily
Glucosylceramide synthase inhibitor
IV infusion
3x/week to every 2 weeks
Glucocerebrosidase (enzyme replacement)
Indications
- Gaucher Disease, Type 1
- Gaucher Disease, Type 1
- Gaucher Disease, Type 3
Dosing
Gaucher Disease, Type 1 100 mg orally three times daily at regular intervals; may reduce to 100 mg once or twice daily for tremor or diarrhea; initiate at 100 mg twice daily for mild renal impairment (CrCl 50-70 mL/min/1.73 m2), 100 mg once daily for moderate impairment (CrCl 30-50 mL/min/1.73 m2); not recommended for severe renal impairment.
Gaucher Disease, Type 1, Gaucher Disease, Type 3 2.5 units/kg three times a week to 60 units/kg once every two weeks, administered intravenously; titrate based on disease severity and therapeutic goals.
Contraindications
—
—
Adverse Reactions
Most common (>=5%) Diarrhea, flatulence, abdominal pain, nausea, weight decrease, headache, tremor, thrombocytopenia
Serious Peripheral neuropathy
Most common headache, dizziness, tachycardia, flushing, hypotension, hypertension, cough, dyspnea, abdominal pain, diarrhea, nausea, vomiting, pruritus, rash, urticaria, back pain, chest discomfort, chills, fatigue, infusion-site burning, infusion-site discomfort, infusion-site swelling, pyrexia
Serious anaphylaxis, hypersensitivity reactions, pneumonia, pulmonary hypertension, angioedema, cyanosis
Pharmacology
Miglustat is a competitive and reversible inhibitor of glucosylceramide synthase, reducing glycosphingolipid biosynthesis so that the residual activity of deficient glucocerebrosidase can more effectively degrade glucosylceramide substrate (substrate reduction therapy).
Imiglucerase is a recombinant analogue of human beta-glucocerebrosidase that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide; mannose-terminated oligosaccharide chains mediate binding to and uptake into macrophages and other target cells, replacing deficient enzyme activity in Gaucher disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zavesca
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Cerezyme
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Zavesca
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Cerezyme
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Zavesca
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Cerezyme
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Gaucher Disease - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Gaucher Disease - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZavescaView full Zavesca profile
CerezymeView full Cerezyme profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.